Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
All business segments have returned to normalcy post the pandemic, and are performing well.
The company has reported a total income of Rs. 127.11 crore during the period ended December 31, 2020.
The specialty intermediate plant shall reduce dependency on Chinese supplies and shall make the company self-reliant on several raw materials requirements.
The company posted net profit of Rs. 48.30 crore for the period ended December 31, 2020.
NFIL has reported a total income of Rs. 898.71 crore during the 9 months period ended December 31, 2020 .
EBITDA at Rs. 34 crore as against Rs. 30.1 crore, up by 13% and PAT stood at Rs. 21.6 crore as against Rs. 18.3 crore, higher by 18%.
The companies also agree to establish a $1 billion maximum escrow account to address potential future PFAS liabilities.
The company remains confident of achieving >25% revenue growth in specialty chemicals in FY21
BOPET-PTA/MEG has been softening from peak, and was Rs72 in Q3FY21, down 10.7% QoQ, but BOPP-PP spreads have been strong at Rs67 (vs Rs60 in Q2FY21).
The PP material for MB filters developed by Lotte Chemical has passed the KF94 performance tests
Tripathi is a 1985 batch IAS officer of Karnataka cadre.
The company has reported total income of Rs.243.05 crores during the 9 months period ended December 31, 2020.
The company has reported total income of Rs.158.06 crores during the 9 months ended December 31, 2020.
With these measures, cost savings of more than €200 million annually should be realized as of 2023.
With this 5000 ton-production increase, Kureha will further enhance its stable and efficient supply of differentiated and quality PPS resins
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Expects to integrate the new product portfolio within a short period of time
INOVYN will provide state of the art BICHLOR bipolar electrolysers for a new 33,000 square meter facility.
Subscribe to our newsletter & stay updated.